<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Britta</forename><surname>Galling</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy</orgName>
								<orgName type="institution">Charit e-Universit€ atsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Hofstra Northwell School of Medicine</orgName>
								<address>
									<settlement>Hempstead</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexandra</forename><surname>Rold An</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Psychiatry</orgName>
								<orgName type="department" key="dep2">Institut d&apos;Investigaci o Biome `dica Sant Pau</orgName>
								<orgName type="institution" key="instit1">Hospital de la Santa Creu i Sant Pau</orgName>
								<orgName type="institution" key="instit2">Universitat Aut onoma de Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katsuhiko</forename><surname>Hagi</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Zucker Hillside Hospital, Psychiatry Research</orgName>
								<orgName type="institution" key="instit2">Northwell Health</orgName>
								<address>
									<settlement>Glen Oaks</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Sumitomo Dainippon Pharma Co</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Liz</forename><surname>Rietschel</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">University Hospital of Child and Adolescent Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">University of Bern</orgName>
								<address>
									<settlement>Bern</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frozan</forename><surname>Walyzada</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Zucker Hillside Hospital, Psychiatry Research</orgName>
								<orgName type="institution" key="instit2">Northwell Health</orgName>
								<address>
									<settlement>Glen Oaks</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wei</forename><surname>Zheng</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">Guangzhou Brain Hospital</orgName>
								<orgName type="institution" key="instit2">Affiliated Hospital of Guangzhou Medical University</orgName>
								<address>
									<settlement>Guangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xiao-Lan</forename><surname>Cao</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Chinese University of Hong Kong</orgName>
								<address>
									<settlement>Hong Kong SAR</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yu-Tao</forename><surname>Xiang</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Faculty of Health Sciences</orgName>
								<orgName type="laboratory">Unit of Psychiatry</orgName>
								<orgName type="institution">University of Macao</orgName>
								<address>
									<settlement>Taipa, Macao</settlement>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution">SAR</orgName>
								<address>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mathias</forename><surname>Zink</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Medical Faculty Mannheim</orgName>
								<orgName type="institution" key="instit1">Central Institute of Mental Health</orgName>
								<orgName type="institution" key="instit2">Heidelberg University</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">John</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Zucker Hillside Hospital, Psychiatry Research</orgName>
								<orgName type="institution" key="instit2">Northwell Health</orgName>
								<address>
									<settlement>Glen Oaks</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Hofstra Northwell School of Medicine</orgName>
								<address>
									<settlement>Hempstead</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">Feinstein Institute for Medi-cal Research</orgName>
								<address>
									<settlement>Manhasset</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="institution">Albert Einstein College of Medicine</orgName>
								<address>
									<settlement>Bronx</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jimmi</forename><surname>Nielsen</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Aalborg University Hospital</orgName>
								<address>
									<settlement>Aalborg</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Clinical Medicine</orgName>
								<orgName type="institution">Aalborg University</orgName>
								<address>
									<settlement>Aalborg</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Leucht</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Klinik und Poliklinik f€ ur Psychiatrie und Psychotherapie</orgName>
								<orgName type="institution">Technische Universit€ at M€ unchen</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Zucker Hillside Hospital, Psychiatry Research</orgName>
								<orgName type="institution" key="instit2">Northwell Health</orgName>
								<address>
									<settlement>Glen Oaks</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Hofstra Northwell School of Medicine</orgName>
								<address>
									<settlement>Hempstead</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">Feinstein Institute for Medi-cal Research</orgName>
								<address>
									<settlement>Manhasset</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="institution">Albert Einstein College of Medicine</orgName>
								<address>
									<settlement>Bronx</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">C128F7330D7C0D3C6948C2E320B6F53D</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:35+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Antipsychotics</term>
					<term>polypharmacy</term>
					<term>augmentation</term>
					<term>monotherapy</term>
					<term>schizophrenia</term>
					<term>clozapine</term>
					<term>aripiprazole</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and costly with unclear evidence for its efficacy and safety.</s><s>We conducted a systematic literature search and a random effects meta-analysis of randomized trials comparing augmentation with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia.</s><s>Co-primary outcomes were total symptom reduction and study-defined response.</s><s>Antipsychotic augmentation was superior to monotherapy regarding total symptom reduction (16 studies, N5694, standardized mean difference, SMD5-0.53,</s><s>95% CI: 20.87 to 20.19, p50.002).</s><s>However, superiority was only apparent in open-label and low-quality trials (both p&lt;0.001), but not in double-blind and high-quality ones (p50.120 and 0.226, respectively).</s><s>Study-defined response was similar between antipsychotic augmentation and monotherapy (14 studies, N5938, risk ratio 5 1.19, 95% CI: 0.99 to 1.42, p50.061), being clearly non-significant in double-blind and high-quality studies (both p50.990).</s><s>Findings were replicated in clozapine and nonclozapine augmentation studies.</s><s>No differences emerged regarding all-cause/specific-cause discontinuation, global clinical impression, as well as positive, general and depressive symptoms.</s><s>Negative symptoms improved more with augmentation treatment (18 studies, N5931, SMD5-0.38,</s><s>95% CI: 20.63 to 20.13, p&lt;0.003), but only in studies augmenting with aripiprazole (8 studies, N5532, SMD5-0.41,</s><s>95% CI: 20.79 to 20.03, p50.036).</s><s>Few adverse effect differences emerged: D2 antagonist augmentation was associated with less insomnia (p50.028),</s><s>but more prolactin elevation (p50.015), while aripiprazole augmentation was associated with reduced prolactin levels (p&lt;0.001) and body weight (p50.030).</s><s>These data suggest that the common practice of antipsychotic augmentation in schizophrenia lacks double-blind/high-quality evidence for efficacy, except for negative symptom reduction with aripiprazole augmentation.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Management options for patients with schizophrenia remain suboptimal, as indicated by insufficient symptom control in a sizable subgroup of patients and low response rates, frequently leading to functional impairment <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> .</s><s>Recommendations after inadequate antipsychotic response include waiting for a delayed response, dose adjustment, switching to another antipsychotic, and -in case of treatment resistance to at least two adequate antipsychotic trials -clozapine treatment <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> .</s><s>Another adopted strategy is antipsychotic polypharmacy <ref type="bibr" target="#b11">12</ref> .</s><s>Limited data on clinicians' reasoning suggest various motivations for this strategy, including attempts to increase/speed up efficacy, treat residual positive symptoms, or reduce adverse effects allowing dose reduction of the first antipsychotic <ref type="bibr" target="#b12">13</ref> .</s><s>Antipsychotic polypharmacy has been reported as a common clinical practice <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15</ref> , sometimes implemented by clinicians before or instead of trying clozapine <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b15">16</ref> .</s><s>Although the frequency of antipsychotic polypharmacy varies according to patient, illness, setting and provider variables <ref type="bibr" target="#b16">17</ref> , rates in schizophrenia commonly range between 10 and 30% <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref> .</s></p><p><s>Despite common use, the evidence for the efficacy and tolerability of antipsychotic polypharmacy is weak <ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref> .</s><s>In fact, guidelines reserve augmentation with a second antipsychotic as a last-stage treatment option after clozapine failure, intolerability or rejection <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref> .</s><s>Additionally, concerns about antipsychotic polypharmacy include the potential for drug-drug interactions, decreased adherence due to complex drug regimes, higher cost <ref type="bibr" target="#b23">[23]</ref><ref type="bibr" target="#b24">[24]</ref><ref type="bibr" target="#b25">[25]</ref> , and increased adverse effects <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b22">22,</ref><ref type="bibr" target="#b26">[26]</ref><ref type="bibr" target="#b27">[27]</ref><ref type="bibr" target="#b28">[28]</ref><ref type="bibr" target="#b29">[29]</ref> .</s></p><p><s>Meta-analyses aggregate the information of conceptually similar studies and consolidate their quantitative outcomes using statistics.</s><s>The derived pooled estimates of treatment efficacy and safety are more robust compared to primary study results.</s><s>Moreover, meta-analyses enable researchers to contrast results from multiple studies and to identify patterns of common effects across studies, or reasons for outcome variability.</s><s>However, to facilitate informative results and meaningful subgroup and meta-regression analyses, the study methodology should be as homogeneous as possible; study quality should be taken into account; and the total population studied should be sufficiently large (1000 subjects) <ref type="bibr" target="#b30">30</ref> .</s></p><p><s>Although four meta-analyses examined the efficacy of antipsychotic polypharmacy, either irrespective of the antipsychotics used <ref type="bibr" target="#b19">20</ref> or restricted to clozapine-treated patients <ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref> , their results remained somewhat inconclusive, possibly influenced by: a) mixing together antipsychotic augmentation (adding a second antipsychotic after non-response to the first) and co-initiation (combination of two antipsychotics from the beginning) strategies <ref type="bibr" target="#b19">20</ref> ; b) lack of separating lower from higher quality studies <ref type="bibr" target="#b19">20</ref> , and c) the relatively low number of available studies and patients treated in an augmentation paradigm <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref> .</s></p><p><s>In one of those meta-analyses, polypharmacy was associated with significantly greater response than monotherapy, with a number-needed-to-treat of 7 <ref type="bibr" target="#b19">20</ref> .</s><s>However, the improved response was moderated by studies lasting at least ten weeks, conducted in China, examining co-initiation and involving clozapine.</s><s>Further, that meta-analysis only included six studies of antipsychotic augmentation (N5197), and did not assess symptom reduction due to lacking data.</s></p><p><s>The three remaining meta-analyses focused on combination treatments with clozapine, either mixing co-initiation and augmentation studies together <ref type="bibr" target="#b21">21</ref> , or focusing on augmentation studies but analyzing only individual drug combinations <ref type="bibr" target="#b32">32</ref> , or focusing only on symptom reduction and not response rates <ref type="bibr" target="#b31">31</ref> .</s><s>One meta-analysis found clozapine co-treatment to be superior to clozapine monotherapy, but this finding was only apparent in open-label studies <ref type="bibr" target="#b21">21</ref> .</s><s>In one other meta-analysis, augmentation of clozapine with a second antipsychotic was associated with a small benefit (effect size 5 0.239, p50.028), but only 14 trials and 714 patients provided data, and higher versus lower quality studies were not analyzed separately <ref type="bibr" target="#b31">31</ref> .</s></p><p><s>Due to the limitations of those prior meta-analyses, the frequent use of antipsychotic polypharmacy in ordinary practice, and the recent publication of many additional studies, we conducted a new systematic review and meta-analysis comparing the efficacy and adverse effects of antipsychotic augmentation vs. monotherapy.</s><s>Based on the prior literature <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref> , we hypothesized that antipsychotic augmentation would not be superior to monotherapy regarding efficacy (measured as total and specific symptom reduction as well as response/remission/ relapse) when focusing on augmentation trials and those with higher quality, but that antipsychotic augmentation might confer a higher risk of adverse effects (except for reduction of specific adverse effects when adding a partial D2 agonist to D2 antagonists).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard <ref type="bibr" target="#b35">35,</ref><ref type="bibr" target="#b36">36</ref> .</s><s>At least two independent authors searched PubMed/MEDLINE, PsycINFO, Chinese Journal Net, Wangfan, and China Biology Medicine databases from inception until May 25, 2015, without language restrictions, supplemented by a manual review of reference lists from eligible publications and relevant reviews.</s><s>Authors were contacted for additional information if needed.</s></p><p><s>We included randomized controlled trials with samples consisting of at least 20 adults with a diagnosis of schizophrenia or schizoaffective disorder; in which patients were assigned to augmentation of the current antipsychotic with a different antipsychotic versus augmentation with placebo (in blinded studies) or continuation of existing antipsychotic monotherapy; and in which meta-analyzable data were reported, including symptomatic/ functional or adverse effect outcomes.</s><s>We excluded studies comparing antipsychotic monotherapy versus two antipsychotics started concurrently, as well as those comparing antipsychotic augmentation with antipsychotic switch instead of continuation of the original antipsychotic monotherapy.</s></p><p><s>Co-primary outcomes were total symptom reduction, as assessed by the Positive and Negative Syndrome Scale (PANSS) <ref type="bibr" target="#b37">37</ref> or the Brief Psychiatric Rating Scale (BPRS) <ref type="bibr" target="#b38">38</ref> , and study-defined treatment response.</s><s>Secondary outcomes were all-cause and specific-cause discontinuation (inefficacy, intolerability); reduction of positive symptoms (as assessed by the PANSS positive, the BPRS positive, or the Scale for the Assessment of Positive Symptoms, SAPS <ref type="bibr" target="#b39">39</ref> ), of negative symptoms (as assessed by the PANSS negative, the BPRS negative, or the Scale for the Assessment of Negative Symptoms, SANS <ref type="bibr" target="#b40">40</ref> ), and of general symptoms (as assessed by the PANSS general); reduction of global illness severity (as assessed by the Clinical Global Impression Scale -Improvement, CGI-I 41 ); reduction of depressive symptoms (as assessed by the PANSS/BPRS anxiety/depression, the Hamilton Scale for Depression, HAM-D <ref type="bibr" target="#b42">42</ref> , or the Calgary Depression Scale for Schizophrenia, CDSS <ref type="bibr" target="#b43">43</ref> ); improvement of functioning (as evaluated by the Global Assessment of Functioning Scale, GAF <ref type="bibr" target="#b44">44</ref> ); and frequency and severity of adverse effects.</s></p><p><s>Data of each study were independently identified, checked and extracted by at least two authors, including information relevant for the Cochrane risk-of-bias tool <ref type="bibr" target="#b45">45</ref> .</s><s>Inconsistencies were resolved by consensus/involvement of a third reviewer.</s></p><p><s>We conducted a random effects <ref type="bibr" target="#b46">46</ref> meta-analysis of outcomes using Comprehensive Meta-Analysis V3 (www.meta-analysis.</s><s>com).</s><s>Study heterogeneity was explored using I 2 statistics and chi-square test of homogeneity, with I 2 &gt;50% and p&lt;0.05 indicating significant heterogeneity.</s><s>All analyses were two-tailed with alpha50.05,</s><s>without adjustments for multiple comparisons.</s></p><p><s>For "total" and "specific" psychopathology (except depression and negative symptoms) and for inefficacy-related discontinuation, all studies except those focusing on the amelioration of adverse effects were analyzed.</s><s>The reason for using this restricted data set was that studies focusing on the amelioration of adverse effects could have included treatment responders, leaving little or no room for improvement.</s><s>In contrast, for depression and negative symptoms and for individual adverse effects, all-cause discontinuation and intolerability-related discontinuation, all available data were analyzed, including studies focusing on the reduction of adverse effects.</s></p><p><s>Group differences in continuous outcomes were analyzed as the pooled standardized mean difference (SMD) in either change from baseline to endpoint (preferred) or endpoint scores (only preferred if change score results were skewed, i.e., SD &gt; twice the mean).</s><s>Additionally, weighted mean difference (WMD) was calculated for weight change in kilograms.</s><s>Dichotomous data were analyzed calculating the pooled risk ratio (RR).</s><s>Intention-to-treat (ITT) data were always preferred, but observed cases (OC) data were also allowed.</s></p><p><s>All outcomes were analyzed for the pooled sample and for high-quality studies separately.</s><s>The latter were defined a priori as double-blind studies using ITT/last-observation-carriedforward (LOCF) analyses, as opposed to open-label studies and those using OC data.</s><s>In two studies with more than one active augmentation arm <ref type="bibr" target="#b47">47,</ref><ref type="bibr" target="#b48">48</ref> , the number of patients in the monotherapy group was divided by the number of active study arms to avoid double-counting of control subjects.</s></p><p><s>For meta-regression analyses, the baseline BPRS total scores were converted to PANSS total scores using equipercentile linking <ref type="bibr" target="#b49">49</ref> .</s><s>Exploratory subgroup and meta-regression analyses were added post-hoc for negative symptom change (the only overall significant outcome in both low-and high-quality studies) in studies using partial D2 agonists.</s></p><p><s>We inspected funnel plots, used Egger's regression test 50 and the Duval and Tweedie's trim and fill method <ref type="bibr" target="#b51">51</ref> to quantify whether publication bias could have influenced the results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>The initial search resulted in 17,653 hits.</s><s>Altogether, 17,427 studies were excluded at the title/abstract level.</s><s>Of the remaining 226 references, 195 were excluded after full text review, yielding 31 studies that were included in the meta-analysis (Figure <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy of antipsychotic monotherapy vs. augmentation (efficacy data set)</head><p><s>Details on the 22 meta-analyzed studies with efficacy as the primary outcome (N51,342) are provided in Table <ref type="table" target="#tab_0">1</ref>.</s><s>They included 13 double-blind and ITT/LOCF "high-quality" studies and 9 open-label and/or OC "low quality" ones.</s></p><p><s>Antipsychotic augmentation was superior to monotherapy regarding total symptom reduction (16 studies, N5694, SMD 5-0.53, 95% CI: 20.87 to 20.19, p50.002), but only in openlabel (n56, N5285, SMD5-0.81,</s><s>95% CI: 21.18 to 20.43, p&lt;0.001) and low-quality (n57, N5316, SMD5-0.83,</s><s>95% CI: 21.16 to 20.50, p&lt;0.001) studies, not in double-blind (n510, N5409, SMD5-0.37,</s><s>95% CI: 20.83 to 0.10, p50.120) and high-quality (n59, N5378, SMD5-0.30,</s><s>95% CI: 20.78 to 0.19, p50.226) ones (Figures <ref type="figure">2 and 3</ref>).</s><s>The funnel plots and Egger's test did not indicate publication bias (p50.320).</s></p><p><s>In subgroup analyses, antipsychotic augmentation was superior in certain settings (only inpatients: n56, N5316, SMD5-0.82,</s><s>95% CI: 21.22 to 20.43, p&lt;0.001;</s><s>only outpatients: n55, N5247, SMD5-0.76,</s><s>95% CI: 21.49 to 20.03, p50.042) and regions</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 2</head><p><s>Forest plots of overall symptom reduction and study-defined response.</s><s>SMD -standardized mean difference, RR -risk ratio</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 3</head><p><s>Primary outcomes, subgroup analyses and meta-regression in studies with efficacy as primary outcome.</s><s>SMD -standardized mean difference, RR -risk ratio, CLZ -clozapine, SGA -second generation antipsychotic, FGA -first generation antipsychotic, AP -antipsychotic (China: n55, N5269, SMD520.86,</s><s>95% CI: 21.27 to 20.45, p&lt;0.001; non-North American/European countries: n58, N5374, SMD5-0.71,</s><s>95% CI: 21.05 to 20.37, p&lt;0.001).</s><s>However, superiority in these subgroups was not apparent in high-quality studies (Figure <ref type="figure">3</ref>).</s><s>Findings regarding symptom reduction were replicated in augmentation studies of clozapine with a second generation antipsychotic (SGA) or a first generation antipsychotic (FGA) (n514, N5612, SMD5-0.52,</s><s>95% CI: 20.90 to 20.14, p50.007), clozapine with a SGA (n512, N5528, SMD5-0.52,</s><s>95% CI: 20.93 to 20.11, p50.012), and non-clozapine SGA with a SGA (n52, N582, SMD5-0.71,</s><s>95% CI: 21.16 to 20.26, p50.002); studies augmenting with a partial D2 agonist (n54, N5214, SMD5-0.57,</s><s>95% CI: 21.10 to 20.03, p50.039), and those augmenting with D2 antagonists (n512, N5480, SMD5-0.52,</s><s>95% CI: 20.95 to 20.08, p50.019).</s><s>Results persisted independent of the non-response definition (strict, 2 adequate trial failures vs. lenient, 1 adequate trial failure): respectively, n513, N5542, SMD5-0.41,</s><s>95% CI: 20.79 to 0.03, p50.035; and n52, N586, SMD5-1.15,</s><s>95% CI: 21.61 to 20.70, p&lt;0.001).</s><s>However, again, differences were nonsignificant when analyzing only high-quality studies (Figure <ref type="figure">3</ref>).</s></p><p><s>In meta-regression analyses, a higher augmentation-tomonotherapy ratio of chlorpromazine equivalent dose (p50.019) and higher baseline PANSS/converted BPRS scores (p50.011) were associated with less symptom improvement, while studies with high risk of bias near-significantly moderated greater improvement with antipsychotic augmentation (p50.050).</s><s>The influence of the PANSS/converted BPRS scores was replicated in high-quality studies (p50.033),</s><s>whereas the other factors were non-significant.</s></p><p><s>Response, as defined by 20% PANSS/BPRS reduction (n510), 25% PANSS reduction (n53), and 20% PANSS reduction or CGI-I of 1 or 2 (n51), did not differ between antipsychotic augmentation and monotherapy (n514, N5938, RR51.19, 95% CI: 0.99 to 1.42, p50.061).</s><s>In subgroup analyses, antipsychotic augmentation was superior in open-label/ low-quality studies (n54, N5245, RR51.30, 95% CI: 1.04 to 1.64, p50.024), but not in double-blind/high-quality ones (n510, N5693, RR51.00, 95% CI: 0.72 to 1.39, p50.990) (Figure <ref type="figure">2</ref>).</s><s>The funnel plots and Egger's test did not indicate publication bias (p50.508).</s></p><p><s>Antipsychotic augmentation was again superior in inpatient only studies (n54, N5207, RR51.67, 95% CI: 1.00 to 2.77, p50.049),</s><s>Chinese studies (n54, N5245, RR51.30, 95% CI: 1.04 to 1.64, p50.024) and non-North American/European studies (n55, N5273, RR51.35, 95% CI: 1.06 to 1.73, p50.017) (Figure <ref type="figure">3</ref>).</s><s>In these subgroups, the number of high-quality studies was 1, not allowing for separate analyses.</s><s>There was no advantage of any specific antipsychotic combination, or depending on nonresponse definition.</s><s>No significant moderator of treatment response emerged.</s><s>No between-group differences were observed regarding inefficacy-related discontinuation (n56, N5596, RR51.08, 95% CI: 0.44 to 2.67, p50.870), global clinical impression (n58, N5403, SMD5-0.01,</s><s>95% CI: 20.32 to 0.30, p50.947), positive symptoms (n514, N5604, SMD5-0.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy and tolerability of antipsychotic monotherapy vs. augmentation (complete data set)</head><p><s>The complete data set (efficacy-focused plus adverse effectfocused studies) included 31 trials (N52,073) (see Table <ref type="table" target="#tab_0">1</ref>).</s><s>The mean PANSS/converted BPRS score was higher in efficacy-focused studies (total sample 5 79.7 6 10.8, clozapine studies 5 79.3 6 9.6, non-clozapine studies 5 81.7 6 15.9) than in adverse-effect focused ones (total sample 5 67.4 6 9.2, clozapine studies 5 71.5, non-clozapine studies 5 66.6 6 9.9).</s></p><p><s>All-cause discontinuation (n522, N51,482, RR51.13, 95% CI: 0.90 to 1.42, p50.284), and intolerability-related discontinuation (n511, N5949, RR50.87, 95% CI: 0.50 to 1.50, p50.611) did not differ between antipsychotic augmentation and monotherapy.</s></p><p><s>Negative symptoms improved with antipsychotic augmentation (n518, N5931, SMD5-0.38,</s><s>95% CI: 20.63 to 20.13, p50.003), but in subgroup analyses this effect was only significant in studies augmenting D2 antagonists with a partial D2 agonist (n58, N5532, SMD5-0.41,</s><s>95% CI: 20.79 to 20.03, p50.036), not when combining two D2 antagonists (n510, N5399, SMD5-0.36,</s><s>95% CI: 20.72 to 0.01, p50.055).</s><s>These findings were replicated in high-quality studies (4 trials augmenting D2 antagonists with a partial D2 agonist, N5355, SMD5-0.28,</s><s>95% CI: 20.55 to 20.009, p50.043).</s><s>In exploratory subgroup and meta-regression analyses, no relevant moderator of negative symptom improvement with a partial D2 agonist emerged.</s></p><p><s>Antipsychotic augmentation and monotherapy did not differ regarding depressive symptoms (n510, N5351, SMD5 20.69, 95% CI: 21.42 to 0.05, p50.066).</s></p><p><s>Few differences in adverse effects emerged.</s><s>D2 antagonist augmentation was associated with less insomnia (n53, N5169, RR50.26, 95% CI: 0.08 to 0.86, p50.028), but more prolactin elevation (n52, each representing augmentation with risperidone, N574, SMD52.20,</s><s>95% CI: 0.43 to 3.96, p50.015), while aripiprazole augmentation of D2 antagonists was associated with reduced prolactin levels (n59, N5450, SMD5-1.60,</s><s>95% CI: 22.19 to 21.01, p&lt;0.001) and body weight (n56, N5260, WMD5-0.93,</s><s>95% CI5 21.77 to 20.09, p50.030).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>While some prior meta-analyses have examined the efficacy of combination or "polypharmacy" strategies in schizophrenia <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref> , this is the first meta-analysis of randomized controlled trials focusing exclusively on augmentation strategies (i.e., the addition of a second antipsychotic after non-response to the first) versus continued treatment with one antipsychotic (with addition of placebo in the blinded studies), irrespective of the baseline antipsychotic.</s></p><p><s>World Psychiatry 16:1 -February 2017</s></p><p><s>Although our prior meta-analysis, published in 2009 <ref type="bibr" target="#b19">20</ref> , included 19 studies and 1,229 patients, merely 6 studies with only 197 patients were "augmentation" studies, which are the ones that are truly relevant, as they clinically reflect the management of refractory/non-responsive patients.</s><s>In the current study, we increased the meta-analyzed data from 6 to 31 studies and 197 to 2,073 patients.</s><s>This greater number of studies allowed for an evaluation of various symptom domains beyond study-defined response, plus the assessment of adverse effects and subgroup and meta-regression analyses, including examination of the effect of open versus blinded trials.</s></p><p><s>In contrast to that prior meta-analysis <ref type="bibr" target="#b19">20</ref> , in which response rates had been significantly greater in the antipsychotic polypharmacy group that mixed co-initiation and augmentation trials (number-needed-to-treat 5 7), the current meta-analysis did not provide any evidence for enhanced efficacy of antipsychotic augmentation in high-quality, blinded studies for either antipsychotic response or symptom reduction.</s><s>This finding suggests that expectation and salience biases, also present in clinical care, may underlie observed improvements and decision making when augmenting one antipsychotic with a second one.</s></p><p><s>Although in efficacy-focused studies total symptoms decreased significantly more in the augmentation group, this effect was driven by open-label studies and those using OC analyses.</s><s>Notably, the non-significance regarding total symptom reduction in high-quality studies was not driven by fewer studies and widening of the confidence intervals.</s><s>Rather, more high-quality than low-quality studies were included (nine vs. seven), and the confidence intervals remained almost identical, whereas the between-group effect size was much smaller in high-quality studies.</s><s>Furthermore, in efficacy-focused studies, no difference between antipsychotic augmentation and monotherapy was found regarding response rate, but, again, in the subgroup of low-quality studies superiority of the augmentation arm was observed.</s></p><p><s>Evidence regarding symptom improvement and treatment response was lacking for augmentation of either clozapine or non-clozapine antipsychotics (with the latter studies being surprisingly uncommon).</s><s>The previously identified benefit regarding augmentation of clozapine with a second antipsychotic <ref type="bibr" target="#b31">31</ref> could not be confirmed in blinded trials and those using ITT data.</s><s>Prior meta-analyses that focused on antipsychotic co-treatment strategies involving clozapine <ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref> had much fewer studies (augmentation studies: 5-14 vs. 20 in our metaanalysis; patients: 187-734 vs. 1,112 in our meta-analysis) and in one instance <ref type="bibr" target="#b21">21</ref> combined antipsychotic augmentation and co-initiation trials.</s></p><p><s>Despite the overall unfavorable results in high-quality studies for total, positive and general symptoms, global clinical impression, depression, treatment response and study discontinuation, augmentation of D2 antagonists with a partial D2 agonist was associated with significantly reduced negative symptoms, a finding that was confirmed in high-quality studies.</s><s>Since the treatment of negative symptoms remains a big challenge in schizophrenia <ref type="bibr" target="#b81">81,</ref><ref type="bibr" target="#b82">82</ref> , these findings, based on eight studies (including four high-quality trials) clearly require further investigation, especially comparing augmentation with a partial D2 agonist versus switching to a partial D2 agonist.</s><s>Since two new partial D2 agonists, brexpiprazole <ref type="bibr" target="#b83">83</ref> and cariprazine <ref type="bibr" target="#b84">84</ref> , were recently approved for schizophrenia, it will be of interest to see if the potential benefits for negative symptoms extend to these other agents.</s></p><p><s>Different from the generally held notion that antipsychotic polypharmacy carries a greater risk of adverse effects <ref type="bibr" target="#b22">22</ref> , this was only found regarding greater prolactin elevation when combining two D2 antagonists.</s><s>Rather, combination of two D2 antagonists was associated with less insomnia, whereas augmentation with the partial D2 agonist aripiprazole resulted in lower prolactin levels and reduced body weight.</s></p><p><s>The lack of superior efficacy of antipsychotic augmentation in high-quality studies is in contrast to common clinical belief and practice, where antipsychotic co-treatment is often implemented for non-response to antipsychotic monotherapy <ref type="bibr" target="#b11">12</ref> .</s><s>However, the clinical evaluation of improvement with antipsychotic augmentation mirrors the findings from open-label studies, suggesting that in clinical settings the expectations of patients and clinicians may translate into perceived favorable outcomes.</s><s>Large pragmatic randomized controlled trials of antipsychotic augmentation strategies conducted in generalizable settings and samples are needed to confirm the lack of efficacy advantages of antipsychotic augmentation, as we cannot fully rule out a selection bias of less severely ill patients agreeing to participate in blinded trials.</s><s>However, this possibility seems relatively low, since mean baseline PANSS/converted BPRS total symptom severity was around 80 in these pretreated individuals, and PANSS/converted BPRS total symptom severity did not significantly moderate the results.</s></p><p><s>In meta-regression analyses, less symptom improvement was associated with a higher chlorpromazine equivalent dose in the augmentation versus monotherapy arms, and a greater baseline symptom severity, with the latter relationship remaining significant in high-quality studies.</s><s>These findings suggest that antipsychotic augmentation is even less effective in the sicker patients and those requiring higher antipsychotic doses.</s><s>Alternatively, the higher total antipsychotic doses in the combination groups may be a reflection of lack of initial improvement, prompting dose escalation.</s><s>This relationship might also be due to greater dopamine blockade resulting in less improvement due to secondary negative symptoms or other unfavorable effects.</s></p><p><s>Although the moderation of less efficacy by higher baseline symptom severity contradicts a recent meta-analysis <ref type="bibr" target="#b85">85</ref> , those results pertained to acutely exacerbated patients in whom greater baseline symptom severity created more room for improvement.</s><s>Conversely, in our meta-analysis, a substantial number of patients had likely benefitted to some degree from antipsychotic monotherapy in the past, so that higher residual symptom severity is probably a marker of less treatment responsiveness.</s></p><p><s>The results of this study need to be interpreted within some limitations.</s><s>These include: a) the still relatively small number of double-blind studies comparing antipsychotic augmentation with monotherapy in schizophrenia, particularly for augmentation of non-clozapine antipsychotics and for specific antipsychotic co-treatment pairs; b) the heterogeneous study origin, design, definition and degree of insufficient response to monotherapy, measurements and outcomes; c) the limited number of studies reporting negative and depressive symptoms as well as adverse effects, which were often not comprehensively assessed or reported; d) the potential influence of cultural or ethnic differences (although we addressed regional effects in pre-planned subgroup analyses, yet the effect of studies from China overlapped almost 100% with an efficacy signal only detected in open-label/low-quality studies); e) the exclusion of studies focusing on adverse effects from the efficacy analyses to reduce heterogeneity (supported by a &gt;10point lower mean PANSS/converted BPRS symptom severity in side effect-focused versus efficacy-focused studies); f) the combination of studies augmenting clozapine and non-clozapine antipsychotics, potentially representing different patient subgroups (although mean baseline PANSS/converted BPRS total scores were comparable, and subgroup analyses replicated results in both clozapine and non-clozapine studies); g) the restriction of the distinction between high-quality and lowquality to blinding and data analysis (although risk-of-bias tool clearly confirmed quality differences without having a significant influence in the meta-regression analysis, suggesting that major influencing biases were captured through blinding/ITT categorization); h) the lack of adjustment for multiple comparisons (yet, adjustment for multiple comparisons would only have increased the level of non-significance of differences between groups); i) the potential effect of non-adherence, and j) the lack of detailed data to determine whether the effect of partial agonist augmentation was mainly on primary or secondary negative symptoms.</s></p><p><s>In summary, data from this study suggest that high-quality evidence is lacking for antipsychotic augmentation in patients with schizophrenia, which applies also to patients with inadequate response to clozapine.</s><s>The clinical relevance of the negative symptom advantage of adjunctive partial D2 agonist treatment needs to be further assessed.</s><s>Additionally, effects of augmentation with a partial D2 agonist versus a switch to a partial D2 agonist on negative symptoms need to be compared before these results can be considered for clinical care.</s><s>Antipsychotic augmentation treatment should also be compared with high-dose antipsychotic monotherapy or augmentation with psychosocial interventions.</s><s>Furthermore, non-clozapine antipsychotic augmentation strategies should be compared against a switch to clozapine or to improving adherence, including monotherapy with a long-acting injectable antipsychotic, which are each more rational choices for addressing antipsychotic non-response.</s><s>Another gap is the systematic assessment of adverse effects of antipsychotic augmentation, extending also to cognition, functioning and subjective wellbeing.</s><s>Finally, more high-quality trials are needed that examine antipsychotic augmentation in non-clozapine-treated patients across relevant outcome domains, including patients with carefully defined insufficient response to antipsychotic monotherapy.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 PRISMA diagram of the literature search</s></p></div></figDesc><graphic coords="3,89.86,72.51,432.64,322.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>of low risk judgements, T -total, M -monotherapy, A -augmentation, OL -open label, DB -double blind, ITT -intent to treat, OC -observed cases, CLZ -clozapine, FLU -fluphenazine, PIMpimozide, ARI -aripiprazole, PAL -paliperidone, RIS -risperidone, SER -sertindole, SUL -sulpiride, ZIP -ziprasidone, HAL -haloperidol, QTP -quetiapine, OLZ -olanzapine, NR -not reported</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Study, patient and treatment characteristics</s></p></div></figDesc><table><row><cell></cell><cell>Augmentation group</cell><cell>dose, mg/d: mean (range)</cell><cell></cell><cell>CLZ: FLU:</cell><cell>NR (375-500) NR (25-50)</cell><cell></cell><cell>CLZ: PIM:</cell><cell>518.8 (NR) 6.48 (2.0-8.9)</cell><cell></cell><cell></cell><cell>CLZ: PIM:</cell><cell>NR (NR) 4 (fixed)</cell><cell></cell><cell>CLZ: ARI:</cell><cell>304.3 (NR) 15.5 (5-30)</cell><cell></cell><cell>CLZ: ARI:</cell><cell>397 (NR) 15 (fixed)</cell><cell></cell><cell>CLZ: ARI:</cell><cell>384 (200-900) 11.1 (5-15)</cell><cell></cell><cell>CLZ: ARI:</cell><cell>NR (200-300) NR (20-30)</cell><cell></cell><cell>CLZ: ARI:</cell><cell>310.7 (200-450) 12.5 (10-15)</cell><cell></cell><cell>CLZ: ARI:</cell><cell>168 (75-300) 21.6 (10-30)</cell><cell></cell><cell>CLZ: PAL:</cell><cell>231.7 (NR) 8.2 (6-12)</cell><cell></cell><cell>CLZ: RIS:</cell><cell>456 (200-700) 4 (NR)</cell><cell>CLZ: RIS:</cell><cell>515.6 (300-900) 5.1 (NR)</cell></row><row><cell></cell><cell>Monotherapy dose,</cell><cell>mg/d: mean (range)</cell><cell></cell><cell>CLZ:</cell><cell>NR (375-500)</cell><cell></cell><cell>CLZ:</cell><cell>478.1 (NR)</cell><cell></cell><cell></cell><cell>CLZ:</cell><cell>NR (NR)</cell><cell></cell><cell>CLZ:</cell><cell>290.6 (NR)</cell><cell></cell><cell>CLZ:</cell><cell>400 (NR)</cell><cell></cell><cell>CLZ:</cell><cell>363 (163-900)</cell><cell></cell><cell>CLZ:</cell><cell>NR (300-500)</cell><cell></cell><cell>CLZ:</cell><cell>341.2 (200-450)</cell><cell></cell><cell>CLZ:</cell><cell>368.2 (200-450)</cell><cell></cell><cell>CLZ:</cell><cell>217.9 (NR)</cell><cell></cell><cell>CLZ:</cell><cell>456 (200-700)</cell><cell>CLZ:</cell><cell>414.3 (300-900)</cell></row><row><cell></cell><cell></cell><cell>Setting</cell><cell></cell><cell>Inpatients</cell><cell></cell><cell></cell><cell>Inpatients</cell><cell>(64.2%) and</cell><cell>outpatients</cell><cell>(35.8%)</cell><cell>Outpatients</cell><cell></cell><cell></cell><cell>Inpatients and</cell><cell>outpatients</cell><cell>(% NR)</cell><cell>Outpatients</cell><cell></cell><cell></cell><cell>Outpatients</cell><cell></cell><cell></cell><cell>Inpatients</cell><cell></cell><cell></cell><cell>Outpatients</cell><cell></cell><cell></cell><cell>Inpatients</cell><cell></cell><cell></cell><cell>Inpatients</cell><cell></cell><cell></cell><cell>Outpatients</cell><cell></cell><cell>Inpatients</cell><cell>(20.0%) and</cell><cell>outpatients</cell><cell>(80.0%)</cell></row><row><cell>Trial</cell><cell>duration</cell><cell>(weeks)</cell><cell></cell><cell>24</cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell></cell><cell>8</cell><cell></cell><cell></cell><cell>8</cell><cell></cell><cell></cell><cell>16</cell><cell></cell><cell></cell><cell>16</cell><cell></cell><cell></cell><cell>24</cell><cell></cell><cell></cell><cell>6</cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell></cell><cell>6</cell><cell></cell><cell>6</cell></row><row><cell></cell><cell></cell><cell>Analysis</cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell>OC</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell>OC</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell><cell>ITT</cell></row><row><cell></cell><cell>Primary</cell><cell>outcome</cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell>Adverse</cell><cell>effects</cell><cell></cell><cell>Adverse</cell><cell>effects</cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell><cell>Efficacy</cell></row><row><cell></cell><cell></cell><cell>Blinding</cell><cell></cell><cell>OL</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell></cell><cell>OL</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell></cell><cell>OL</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell><cell>DB</cell></row><row><cell></cell><cell>Risk of</cell><cell>bias*</cell><cell></cell><cell>1</cell><cell></cell><cell></cell><cell>3</cell><cell></cell><cell></cell><cell></cell><cell>4</cell><cell></cell><cell></cell><cell>5</cell><cell></cell><cell></cell><cell>2</cell><cell></cell><cell></cell><cell>4</cell><cell></cell><cell></cell><cell>1</cell><cell></cell><cell></cell><cell>5</cell><cell></cell><cell></cell><cell>1</cell><cell></cell><cell></cell><cell>3</cell><cell></cell><cell></cell><cell>2</cell><cell></cell><cell>6</cell></row><row><cell></cell><cell></cell><cell>No. patients</cell><cell></cell><cell>T: 60</cell><cell>M: 30</cell><cell>A: 30</cell><cell>T: 53</cell><cell>M: 28</cell><cell>A: 25</cell><cell></cell><cell>T: 28</cell><cell>M: 14</cell><cell>A: 14</cell><cell>T: 61</cell><cell>M: 32</cell><cell>A: 29</cell><cell>T: 38</cell><cell>M: 18</cell><cell>A: 20</cell><cell>T: 207</cell><cell>M: 99</cell><cell>A: 108</cell><cell>T: 60</cell><cell>M: 30</cell><cell>A: 30</cell><cell>T: 40</cell><cell>M: 20</cell><cell>A: 20</cell><cell>T: 62</cell><cell>M: 30</cell><cell>A: 32</cell><cell>T: 70</cell><cell>M: 35</cell><cell>A: 35</cell><cell>T: 24</cell><cell>M: 11</cell><cell>A: 13</cell><cell>T: 30</cell><cell>M: 14</cell><cell>A: 16</cell></row><row><cell></cell><cell></cell><cell>Study Agents</cell><cell>Clozapine 1 first-generation antipsychotic</cell><cell>Liu et al 52 (China) CLZ 1 FLU</cell><cell></cell><cell></cell><cell>Friedman et al 53 (US) CLZ 1 PIM</cell><cell></cell><cell></cell><cell></cell><cell>Gunduz-Bruce CLZ 1 PIM</cell><cell>et al 54 (US)</cell><cell>Clozapine 1 second-generation antipsychotic</cell><cell>Chang et al 55 (Korea) CLZ 1 ARI</cell><cell></cell><cell></cell><cell>Fan et al 56 (US) CLZ 1 ARI</cell><cell></cell><cell></cell><cell>Fleischhacker et al 57 CLZ 1 ARI</cell><cell>(Europe,</cell><cell>South Africa)</cell><cell>Guan 58 (China) CLZ 1 ARI</cell><cell></cell><cell></cell><cell>Muscatello CLZ 1 ARI</cell><cell>et al 59 (Italy)</cell><cell></cell><cell>Sun et al 60 (China) CLZ 1 ARI</cell><cell></cell><cell></cell><cell>Lin et al 61 (China) CLZ 1 PAL</cell><cell></cell><cell></cell><cell>Freudenreich CLZ 1 RIS</cell><cell>et al 62 (US)</cell><cell>Anil Yagcioglu CLZ 1 RIS</cell><cell>et al 63 (Turkey)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc><div><p><s>Study, patient and treatment characteristics (continued)</s></p></div></figDesc><table><row><cell></cell><cell>Augmentation group</cell><cell>dose, mg/d: mean (range)</cell><cell>CLZ: RIS:</cell><cell>494 (NR) 3 (NR)</cell></row><row><cell></cell><cell>Monotherapy dose,</cell><cell>mg/d: mean (range)</cell><cell>CLZ:</cell><cell>487 (NR)</cell></row><row><cell></cell><cell></cell><cell>Setting</cell><cell>Inpatients</cell><cell>(38.2%) and</cell><cell>outpatients</cell><cell>(61.8%)</cell></row><row><cell>Trial</cell><cell>duration</cell><cell>(weeks)</cell><cell>8</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Analysis</cell><cell>ITT</cell><cell></cell></row><row><cell></cell><cell>Primary</cell><cell>outcome</cell><cell>Efficacy</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Blinding</cell><cell>DB</cell><cell></cell></row><row><cell></cell><cell>Risk of</cell><cell>bias*</cell><cell>6</cell><cell></cell></row><row><cell></cell><cell></cell><cell>No. patients</cell><cell>T: 68</cell><cell>M: 34</cell><cell>A: 34</cell></row><row><cell></cell><cell></cell><cell>Agents</cell><cell>CLZ 1 RIS</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Study</cell><cell>Honer et al 64</cell><cell>(International)</cell><cell>Josiassen et al 65</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1</head><label>1</label><figDesc><div><p><s>Study, patient and treatment characteristics (continued)</s></p></div></figDesc><table><row><cell></cell><cell>Augmentation group</cell><cell>dose, mg/d: mean (range)</cell><cell>RIS: ARI:</cell><cell>5.07 (NR) 20 (fixed)</cell><cell>QTP/RIS: ARI:</cell><cell>513/4.6 10.3 (2-15)</cell><cell>(400-800/4-8)</cell></row><row><cell></cell><cell>Monotherapy dose,</cell><cell>mg/d: mean (range)</cell><cell></cell><cell></cell><cell>QTP/RIS:</cell><cell>516/4.8</cell><cell>(400-800/4-8)</cell></row><row><cell></cell><cell></cell><cell>Setting</cell><cell></cell><cell></cell><cell>Outpatients</cell><cell></cell></row><row><cell>Trial</cell><cell>duration</cell><cell>(weeks)</cell><cell></cell><cell></cell><cell>16</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Analysis</cell><cell></cell><cell></cell><cell>ITT</cell><cell></cell></row><row><cell></cell><cell>Primary</cell><cell>outcome</cell><cell></cell><cell></cell><cell>Efficacy</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Blinding</cell><cell></cell><cell></cell><cell>DB</cell><cell></cell></row><row><cell></cell><cell>Risk of</cell><cell>bias*</cell><cell></cell><cell></cell><cell>1</cell><cell></cell></row><row><cell></cell><cell></cell><cell>No. patients</cell><cell></cell><cell></cell><cell>T: 323</cell><cell>M: 155</cell><cell>A: 158</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>ARI</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Agents</cell><cell></cell><cell></cell><cell>QTP/RIS 1</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(US)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Study</cell><cell></cell><cell></cell><cell>Kane et al 73</cell><cell></cell><cell>Lee et al 74</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>25, 95% CI: 20.66 to 0.16, p50.230), general symptoms (n54, N5144, SMD5-0.73,</s><s>95% CI: 21.91 to 0.46, p50.229), and functioning (n52, N580, SMD5-0.36,</s><s>95% CI: 21.19 to 0.47, p50.389).</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">World Psychiatry 16:1 -February 2017</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENT</head><p><s>This study was supported in part by the Zucker Hillside Hospital National Institute of Mental Health (NIMH) Advanced Center for Intervention and Services Research for the Study of Schizophrenia (grant no.</s><s>P30MH090590).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">One hundred years of schizophrenia: a meta-analysis of the outcome literature</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hegarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Baldessarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="1409" to="1416" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tre</forename><surname>Barnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Davies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1079" to="1087" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Stroup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Mcevoy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="1209" to="1223" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Woerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mcmeniman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="473" to="479" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A systematic review and metaanalysis of recovery in schizophrenia</title>
		<author>
			<persName><forename type="first">E</forename><surname>J€ A€ Askel€ Ainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Juola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hirvonen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1296" to="1306" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Falkai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wobrock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lieberman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Biol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="132" to="191" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Buchanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Buckley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1751" to="1762" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Buchanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kreyenbuhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Kelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="71" to="93" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Practice guideline for the treatment of patients with schizophrenia, second edition</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Lehman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lieberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Dixon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="1" to="56" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>Suppl. 2</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting</title>
		<author>
			<persName><forename type="first">G</forename><surname>Goodwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Fleischhacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Arango</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="520" to="532" />
			<date type="published" when="2008-03">March 2008. 2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Guideline for the prevention and treatment of psychiatric disorders in China</title>
	</analytic>
	<monogr>
		<title level="j">Beijing: Chinese Medical Association</title>
		<imprint>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Chinese Medical Association</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gallego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bonetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="18" to="28" />
			<date type="published" when="2009">2009. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shaikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gallego</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="58" to="62" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ganguly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kotzan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1377" to="1388" />
			<date type="published" when="1998">1998-2000. 2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bartels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mellman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="75" to="84" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Psychiatrists&apos; attitude towards and knowledge of clozapine treatment</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lublin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="965" to="971" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Antipsychotic polypharmacy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gallego</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatr Clin North Am</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="661" to="681" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics</title>
		<author>
			<persName><forename type="first">D</forename><surname>Faries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ascher-Svanum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Psychiatry</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Combination antipsychotic therapy in clinical practice</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Secrest</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatr Serv</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="55" to="59" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rummel-Kluge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Corves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="443" to="457" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2017-02">February 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Does the addition of a second antipsychotic drug improve clozapine treatment?</title>
		<author>
			<persName><forename type="first">C</forename><surname>Barbui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Signoretti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">`</forename><surname>Mule</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="458" to="468" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Safety and tolerability of antipsychotic polypharmacy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gallego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Hert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Drug Saf</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="527" to="542" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder</title>
		<author>
			<persName><forename type="first">Mft</forename><surname>Rupnow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Greenspan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Gharabawi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2815" to="2822" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Cost of antipsychotic polypharmacy in the treatment of schizophrenia</title>
		<author>
			<persName><forename type="first">B</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ascher-Svanum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Faries</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Psychiatry</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">19</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Baandrup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sørensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lublin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Health Econ</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="355" to="363" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Metabolic and cardiovascular adverse effects associated with antipsychotic drugs</title>
		<author>
			<persName><forename type="first">De</forename><surname>Hert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Detraux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Winkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Endocrinol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="114" to="126" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice</title>
		<author>
			<persName><forename type="first">De</forename><surname>Hert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dobbelaere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sheridan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="144" to="158" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Balancing efficacy and safety in treatment with antipsychotics</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CNS Spectr</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="12" to="20" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>Suppl. 17</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Misawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fujii</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Psychiatry</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">118</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Effect sizes in cumulative metaanalyses of mental health randomized trials evolved over time</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Trikalinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Churchill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1124" to="1130" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Augmentation of clozapine with a second antipsychotic -a meta-analysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Gee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="15" to="24" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Sommer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mjh</forename><surname>Begemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Temmerman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1003" to="1011" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations</title>
		<author>
			<persName><forename type="first">O</forename><surname>Freudenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Goff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="323" to="330" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Antipsychotic polypharmacy: evidence based or eminence based?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Stahl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="321" to="322" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Stroup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Berlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Morton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="2008" to="2012" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</title>
		<author>
			<persName><forename type="first">D</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Liberati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tetzlaff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e1000097</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The positive and negative syndrome scale (PANSS) for schizophrenia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fiszbein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Opler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="261" to="276" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Manual for the Expanded Brief Psychiatric Rating Scale</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ventura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lukoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Nuechterlein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Methods Psychiatr Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="227" to="244" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">The Scale for the Assessment of Positive Symptoms (SAPS)</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Andreasen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1984">1984</date>
			<pubPlace>Iowa City</pubPlace>
		</imprint>
		<respStmt>
			<orgName>University of Iowa</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">The Scale for the Assessment of Negative Symptoms (SANS)</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Andreasen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1984">1984</date>
			<pubPlace>Iowa City</pubPlace>
		</imprint>
		<respStmt>
			<orgName>University of Iowa</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title level="m" type="main">Rockville: US Department of Health, Education, and Welfare</title>
		<author>
			<persName><forename type="first">W</forename><surname>Guy</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
	<note>ECDEU assessment manual for psychopharmacology, revised</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">A rating scale for depression</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hamilton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="56" to="62" />
			<date type="published" when="1960">1960</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">A depression rating scale for schizophrenics</title>
		<author>
			<persName><forename type="first">D</forename><surname>Addington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Addington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schissel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="247" to="251" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Global Assessment of Functioning: a modified scale</title>
		<author>
			<persName><forename type="first">Rcw</forename><surname>Hall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychosomatics</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="267" to="275" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials</title>
		<author>
			<persName><forename type="first">Jpt</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gøtzsche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page">5928</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Meta-analysis in clinical trials</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dersimonian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Laird</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Control Clin Trials</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="177" to="188" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study</title>
		<author>
			<persName><forename type="first">J-X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-A</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q-T</forename><surname>Bian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychoneuroendocrinology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="130" to="140" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A placebo-controlled trail of adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Dong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Health Psychol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1288" to="1290" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Equipercentile linking of the BPRS and the PANSS</title>
		<author>
			<persName><forename type="first">S</forename><surname>Leucht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rothe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="956" to="959" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Bias in meta-analysis detected by a simple, graphical test</title>
		<author>
			<persName><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Davey</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="page" from="629" to="634" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">trim and fill&quot; method of accounting for publication bias in meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Duval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tweedie</surname></persName>
		</author>
		<author>
			<persName><surname>Nonparametric</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Stat Assoc</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="89" to="98" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">A control study of clozapine combined with fluphenazine in refractory schizophrenia</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med J Chin People&apos;s Health</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">1274</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><surname>Lindenmayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Alcantara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1289" to="1295" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Gunduz-Bruce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gueorguieva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="344" to="347" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Aripiprazole augmentation in clozapinetreated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="720" to="731" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia</title>
		<author>
			<persName><forename type="first">X</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cpc</forename><surname>Borba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Copeland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="217" to="226" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebocontrolled trial</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Fleischhacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Heikkinen</surname></persName>
		</author>
		<author>
			<persName><surname>Oli E J-P</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1115" to="1125" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">The efficacy and safety of aripiprazole combined with clozapine in the treatment of refractory schizophrenia</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bengbu Med Coll</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1084" to="1086" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">Mra</forename><surname>Muscatello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pandolfo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="93" to="99" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">The study of combining clozapine and aripiprazole for the treatment of negative symptoms of schizophrenia</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med J Chin People&apos;s Health</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2592" to="2594" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Paliperidone ER combined with clozapine in the treatment of patients with refractory schizophrenia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hebei Med</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1668" to="1671" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">O</forename><surname>Freudenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Walsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="90" to="94" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety</title>
		<author>
			<persName><forename type="first">Anil</forename><surname>Ya Gcio Glu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Kivircik</forename><surname>Akdede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Turgut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">I</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="63" to="72" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Clozapine alone versus clozapine and risperidone with refractory schizophrenia</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Honer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Thornton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eyh</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="472" to="482" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Josiassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Joseph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kohegyi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="130" to="136" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Clozapine combined with risperidone in replacement of single clozapine in schizophrenia treatment</title>
		<author>
			<persName><forename type="first">X</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med J Chin People&apos;s Health</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="21" to="22" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine</title>
		<author>
			<persName><forename type="first">E</forename><surname>Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Conley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Ball</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2274" to="2283" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Emborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gydesen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="173" to="178" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Shiloh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zemishlany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aizenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="569" to="573" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">The treatment efficacy of clozapine combined with ziprasidone in refractory schizophrenia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin J Postgrad Med</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="62" to="64" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebocontrolled study</title>
		<author>
			<persName><forename type="first">Mra</forename><surname>Muscatello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pandolfo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mic</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="129" to="133" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Shim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Kelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="1404" to="1410" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">A multicenter, randomized, doubleblind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Goff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1348" to="1357" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Psychopharmacol Neurosci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="60" to="66" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">The effect of aripiprazole on serum levels of Insulinlike Growth factor-1 in schizophrenia treatment with olanzapine</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Ou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Health Psychol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="161" to="163" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Yasui-Furukori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kaneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sugawara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="806" to="812" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">A control study on aripiprazole reduces risperidone-induced weight gain and increase of prolactin in patients with schizophrenia</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Q</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sichuan Ment Health</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="122" to="123" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">The study of aripiprazole on preventing the hyperprolactinemia induced by antipsychotics on female</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Hao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Int Psychiatry</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="69" to="72" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">A control study of aripiprazole combined with low-dose clozapine in female schizophrenia</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychosom Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">3</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kotler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Strous</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Reznik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="23" to="26" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Millan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Steckler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Neuropsychopharmacol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="645" to="692" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rabinowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Berardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bugarski-Kirola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="339" to="342" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Skuban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ouyang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="870" to="880" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zukin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="367" to="373" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Furukawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tanaka</surname></persName>
		</author>
		<idno type="DOI">10.1002/wps.20387</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="14" to="21" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2017-02">February 2017</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
